Allogeneic, TSCM-rich dual CAR-T for the treatment of hematologic malignancies, including multiple myelomaNomination triggers $15 million milestone payment to Poseida, extending cash runway into early 2026Poseida Cell Therapy R&D Day to take place on Thursday, November 14 at 7 am PT / 10 am ETSAN DIEGO, Oct. 17, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with ...